Phytochemical and Anticancer Properties of Cuscuta Reflexa: A Therapeutic Approach for Future Insights

Abstract

Cuscuta reflexa, a parasitic plant, has been traditionally used in medicine for its diverse therapeutic properties. This review will focus on the phytochemical and anticancer potential of C. reflexa to emphasize its future applications in therapy. C. reflexa produced different bioactive compounds that include flavonoids, alkaloids, and phenolic acids with high anticancer properties. These phytochemicals have demonstrated encouraging outcomes in their preclinical trials, blocking the growth of cancer cells, triggering eventual cell death, and altering crucial pathways of signals. Antioxidant, anti-inflammatory and immunomodulatory effects of the plant extracts have also been established, which could lead to the anticancer activity of the plant. C. reflexa has not been exploited fully in modern medicine despite its potential and additional studies are required to help exploit its therapeutic potential. This review gives an overview of the phytochemical profile, anticancer pharmacology, and future trends in the research and development of C. reflexa. The list of current information on C. reflexa can possibly spur the further research of the topic, eventually resulting in the creation of the novel anticancer techniques.

Keywords

Introduction

Fig.1: Phytochemical constituents of Cuscuta reflexa

Fig.2: Morphological character of Cuscuta reflexa

Fig.3: Pharmacological activity of Cuscuta reflexa

Impact on mitochondrial membrane potential

The key role of mitochondria in regulating apoptotic cell death has made the mitochondrial activity of Cuscuta reflexa components a research interest, and studies have continued to indicate that mitochondrial activity inhibition is a major step in the plant anticancer process. Mitochondria are the cell powerhouses, which produce ATP by oxidative phosphorylation, yet play also a role of safeguarding cell survival as they combine various stress signals and identify when a cell survives or dies, it is the process of mitochondrial membrane permeabilization [54]. Normal mitochondria have an electrochemical gradient across the inner membrane with the matrix side being negatively charged compared to the intermembrane space to form a mitochondrial membrane potential, which controls the production of ATP. Such potential is a sensitive indicator of the health and functional state of the mitochondria, and is commonly measured by fluorescent (e.g. JC-1 or tetramethylrhodamine methyl ester) dyes which are accumulated in the mitochondria in proportion to the membrane potential. Upon treating cancer cells with extracts of Cuscuta reflexa, a marked and gradual depolarization of the mitochondrial membrane potential a key commitment point in the apoptotic cascade is seen. Such depolarization is caused by the opening of the mitochondrial permeability transition pore, a large conductance channel, which spans the inner and outer mitochondrial membranes permitting free passage of solutes up to 1500 Daltons, and causing collapse of the electrochemical gradient [55].

The effects of mitochondrial depolarization go much further than the bioenergetic crisis occurring through the absence of ATP production into the cytosol to the release of pro-apoptotic proteins in the mitochondrial intermembrane space in the cytosol. One of these proteins is the cytochrome c which is of particular importance because its release leads to the establishment of the apoptosome a multiprotein complex that includes cytochrome c, Apaf-1, and procaspase-9 that activate the initiator caspase-9 and initiate the proteolytic cascade which results in the demolition of the cells. Some of the other proteins released when mitochondrial permeabilization occurs are Smac/DIABLO, which counteracts inhibitor of apoptosis proteins that would otherwise inhibit caspase activation and apoptosis-inducing factor, which translocates to the nucleus and facilitates chromatin condensation in an apoptotic-independent fashion [56]. Bcl-2 family of proteins tightly controls the mitochondrial pathway of apoptosis by including pro-apoptotic Bax, Bak, Bid and Bad and anti-apoptotic Bcl-2, Bcl-xL and Mcl-1. Research investigating the influence of Cuscuta reflexa to this regulatory system has found a treatment to cause a shift in the balance between pro-apoptotic and anti-apoptotic proteins or both, making mitochondria susceptible to permeabilization. Of special interest is the downregulation of Bcl-2 which is often overexpressed in cancer cells as part of chemoresistance because this process reinstates the capacity of cancer cells to undergo apoptosis in relation to various death stimuli. The depolarization of mitochondrial membrane potential herein observed is therefore not an isolated event but as a result of several upstream signals coming together to focus on the mitochondria and make a final decision to commit to cell death by integrating ROS signaling, p53 activation, and Bcl-2 family modulations into a final decision [57].

Antioxidant and pro-oxidant balance

Cuscuta reflexa and cellular redox status has an interesting paradox which throws light on the complication of pharmacology of plant-based products and the biological actions which vary according to circumstances. On the one hand, comprehensive in vitro studies have shown that Cuscuta reflexa extracts have a strong antioxidant property, which can adequately negate free radicals and prevent the destruction of biological molecules by oxidizing agents. The quantification of these antioxidant properties has been done using several standard methodologies such as the DPPH assay that determines the ability to donate hydrogen atoms or electrons to stabilize the DPPH radical, the ABTS assay that measures the radical scavenging ability with respect to the ABTS cation radical, and the FRAP assay that measures ferric reducing antioxidant ability based on the ability to donate electrons [58]. In these tests, Cuscuta reflexa extracts are repeatedly shown to have a concentration-dependent antioxidant activity, whose activity is comparable to that of standard antioxidants like ascorbic acid, butylated hydroxytoluene or quercetin. This antioxidant activity is consistent with the high amounts of phenolic compounds and flavonoids in the plant that are established radical scavengers because of their ability to delocalize unpaired electrons throughout their aromatic ring systems as well as to chelate transition metal ions that might otherwise catalyze oxidative reactions. These antioxidant properties are rationally supported by the traditional use of Cuscuta reflexa in the conditions linked to oxidative stress, including inflammation, liver diseases, and aging, in which oxidative damage to affected tissues would be predicted [59].

However, ironically, the anticancer properties of Cuscuta reflexa take place not by the antioxidant protection but by its exact opposite the formation of pro-oxidant stress which specifically kills cancer cells. This seeming paradox is clarified by the appreciation of the fact that the biological action of polyphenolic compounds is very context-specific, depending on the concentration, cellular context, presence or absence of metal ions, and the redox potential of the target cells. Cuscuta reflexa constituents may be indeed effective antioxidants at moderate levels in normal tissues, offering protection against oxidative injury, which explains the traditional roles of the plant in the treatment of conditions related to the presence of oxidative stress. Nevertheless, in the case of increased exposure of the cancer cells to larger concentrations, or in response to accumulation of the compounds in the microenvironment of the tumor, the compounds may auto-oxidize or can be involved in redox cycling reactions to produce superoxide, hydrogen peroxide and other reactive oxygen species. Such pro-oxidant challenge is especially harmful to cancer cells, which usually work under the conditions of high basal oxidative stress through the combination of high metabolic rate, mitochondrial dysfunction, and activated oncogenic signaling. This prior oxidative stress implied that the cancer cells were already functioning at the border of redox homeostasis, and any further oxidative stress can drive them past the redox homeostasis to cytotoxicity [60]. The increase in the sensitivity of cancer and normal cells to pro-oxidant challenge has created a therapeutic gap that can be used to selectively treat cancer. Moreover, the same phenolic compounds which function as antioxidants under different conditions may undergo Fenton-type reactions in the presence of transition metal ions like copper or iron which are frequently raised in tumors to form very reactive hydroxyl radicals. This is a situation whereby the duo of oxidant and antioxidant, which are context-dependent in normal tissues in physiological conditions, pro-oxidant in cancer cells in conditions of pathologies, is an ideal characteristic of a chemopreventive or chemotherapeutic agent, which may offer protection against carcinogenesis in normal cells and at the same time destroy cancerous cells that have already developed.

Network pharmacology insights

The classical model of drug action based on individual compounds acting on individual molecular targets has become more than satisfactory in the explanation of the therapeutic action of complex botanical extracts such as those of Cuscuta reflexa. A newer field, network pharmacology, which integrates systems biology and pharmacology, provides a more advanced model of understanding the interaction of the multiple constituents of Cuscuta reflexa with the complex biological networks that comprise the pathogenesis of cancer. This model acknowledges that diseases like cancer are hardly caused by one molecular lesion and that a successful treatment measure can be achieved by regulating a number of nodes in these networks instead of acting on one protein. In the case of Cuscuta reflexa, network pharmacology experiments have identified extraordinarily intricate interaction trends of the various phytochemical compounds of the plant and proteins that control the progression of cancer, especially in lung cancer. The computational methods such as molecular docking, network building and pathway enrichment analysis have been used to predict the possible targets of Cuscuta reflexa compounds and to map the biological pathways that are most likely to be targeted by the extract [61].

The Cuscuta reflexa network pharmacology analysis of the drug in the disease lung cancer presents a more specific image of the multi-targeted mechanism of action of the plant. It involves identifying bioactive compounds in the plant, which is based on the phytochemical profile determined by experimental studies and prediction of possible protein targets of each compound, which is performed using computational tools based on structural similarity to known ligands, inverse docking, or machine learning methods. The compound-target interaction networks that resulted indicate that individual Cuscuta reflexa constituents generally touch on several protein targets, and the reverse, which is that individual cancer-related proteins are interacted with by a high number of different constituents, forms a complex web of interactions that together regulate disease-relevant pathways. Among the key proteins that have been identified to be potential targets are growth factor receptors like EGFR which drives proliferation in most lung cancers, intracellular signaling kinases like PI3K, Akt and mTOR which relay pro-survival signals, transcription factors such as STAT3 and NF-kB that coordinate gene expression programs of inflammation and survival and cell cycle regulators like cyclins and cyclin dependent kinases that manage cell division. The overlapping effect of these various targets by the various components of Cuscuta reflexa is combinatoric and can be more effective than the additive effect of individual compound activities, which is likely to be counteracted by redundant and compensatory responses that usually limit the action of single-target drugs [62].

Pathway enrichment analysis of the identified targets indicates that the collective induction of Cuscuta reflexa components together with multiple cancer process pathways is observed, such as the PI3K-Akt signaling pathway, the MAPK signaling cascade, the p53 tumor suppressor pathway, and the apoptosis and cell cycle progression pathways. This multi-pathway targeting is especially important in the fact that cancer cells usually respond to parallel survival pathways or acquire compensatory responses to enable them to avoid the actions of agents that act on only one pathway. Cuscuta reflexa can potentially produce a lasting and more resistant therapeutic response by acting on several vulnerable nodes in the cancer cell network at the same time. Moreover, network analysis would allow finding out which particular compounds in the complex mixture are the most likely to target the key disease proteins, allowing the prioritization of compounds to be isolated and developed further. The network pharmacology paradigm can also be used to understand why the conventional applications of Cuscuta reflexa are not limited to cancer but to inflammatory diseases, liver disease, and other disorders-the same group of targets that is regulated by the constituents in the plant also takes part in a variety of pathological events, and as such their regulation can have therapeutic effects in a variety of disease pathologies. These network-based insights do not just help us better understand the mechanisms of action of Cuscuta reflexa but also give a rational basis to mode of production of optimized extracts or combinations of isolated compounds that best maximize therapeutic and minimize toxicity effects. With the further development of network pharmacology approaches, the incorporation of more complex algorithms, larger compound-target interaction databases, and experimental verification of the predicted interactions, our knowledge of the multi-targeted anticancer mechanisms of Cuscuta reflexa will continue to grow, and new uses of this fantastic plant may be discovered, as well as improved cancer therapies developed.

THERAPEUTIC APPROACHES AND FUTURE INSIGHTS

Complexity of inflammation and cancer has become one of the most interesting paradigms in the modern oncology, which has essentially transformed the current concept of carcinogenesis and has provided novel platforms of therapeutic intervention. The microenvironment in chronic inflammation, whether caused by an underlying infection, autoimmune disease, or exposure of the environment, is highly favorable to malignant transformation and tumor progression. The relationship between them is so strong that inflammation is currently being treated as an enabling property of cancer- a condition that promotes the acquisition and retention of fundamental hallmarks of malignancy such as persistent proliferation, resistance to apoptosis, angiogenesis, tissue invasion, and metastasis. The mechanistic connections between inflammation and cancer are multi-faceted and multi-layered: inflammatory cells infiltrating the tissues release the reactive oxygen and nitrogen species that can initiate the direct damage of the DNA directly, leading to mutations in tumor suppressor genes and oncogenes; transcription factors such as NF-kB and STAT3 are activated by pro-inflammatory cytokines, including tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6, and promote the expression This microenvironment of pro-carcinogenic inflammation is not just a passive background, but an active contributor to the malignant process, and is usurped by growing cancers to assist its progression and invasion. The identification that inflammation is a predictive and a concomitant event in cancer has significant therapeutic implications since agents that can control inflammatory status can be useful in cancer prevention as well as treatment, by interfering with the tumor-favouring microenvironment that enriches malignancy.

In the framework of this concept Cuscuta reflexa is a plant of significant interest because it has been seen to mediate inflammatory disorders through several mechanisms that comply with the traditional applications of this plant in inflammatory diseases. The high phenolic, flavonoid and terpenoid content of the plant is a molecular basis of its anti-inflammatory effect which has been confirmed by a series of experimental models. Research into the effect of Cuscuta reflexa extracts on the inhibition of inflammatory mediators has shown that it has a significant inhibitory effect on inflammatory mediators such as inhibiting the production of pro-inflammatory cytokines, inhibiting nitric oxide synthesis by downregulating the expression of inducible nitric oxide synthase, and inhibiting the expression of cyclooxygenase-2, the enzyme involved in the production of prostaglandins at inflammatory sites. These effects especially apply to cancer biology since the very same inflammatory pathways involving the activation of NF-kB, STAT3 signaling, COX-2 expression, and cytokine production are the same pathways that tumors use to support a conducive microenvironment. Cuscuta reflexa can potentially block the growth factors, survival signals and angiogenic factors supplied to the tumor by inflammatory cells by dampening these inflammatory cascades and inhibit the progression of cancer, even in tumor cells that have no direct cytotoxic effects, without direct action on the tumor. This idea of attacking the tumor microenvironment instead of the tumor per se is a significant paradigm of contemporary oncology as drugs that inhibit angiogenesis or the immune response may be used, and natural products such as those of Cuscuta reflexa may have its place in that approach.

Pathway enrichment analysis of the identified targets indicates that the collective induction of Cuscuta reflexa components together with multiple cancer process pathways is observed, such as the PI3K-Akt signaling pathway, the MAPK signaling cascade, the p53 tumor suppressor pathway, and the apoptosis and cell cycle progression pathways . This multi-pathway targeting is especially important in the fact that cancer cells usually respond to parallel survival pathways or acquire compensatory responses to enable them to avoid the actions of agents that act on only one pathway. Cuscuta reflexa can potentially produce a lasting and more resistant therapeutic response by acting on several vulnerable nodes in the cancer cell network at the same time. Moreover, network analysis would allow finding out which particular compounds in the complex mixture are the most likely to target the key disease proteins, allowing the prioritization of compounds to be isolated and developed further. The network pharmacology paradigm can also be used to understand why the conventional applications of Cuscuta reflexa are not limited to cancer but to inflammatory diseases, liver disease, and other disorders-the same group of targets that is regulated by the constituents in the plant also takes part in a variety of pathological events, and as such their regulation can have therapeutic effects in a variety of disease pathologies. These network-based insights do not just help us better understand the mechanisms of action of Cuscuta reflexa but also give a rational basis to mode of production of optimized extracts or combinations of isolated compounds that best maximize therapeutic and minimize toxicity effects. With the further development of network pharmacology approaches, the incorporation of more complex algorithms, larger compound-target interaction databases, and experimental verification of the predicted interactions, our knowledge of the multi-targeted anticancer mechanisms of Cuscuta reflexa will continue to grow, and new uses of this fantastic plant may be discovered, as well as improved cancer therapies developed.

CHALLENGES AND CONSIDERATIONS

Although the preclinical results have shown promising signs on the anticancer property of Cuscuta reflexa, there are numerous issues which need to be addressed before this botanical resource can be translated into useful clinical therapies. First and most obvious about these difficulties is the very variability in phytochemical composition due to the parasitic nature of the plant, which adds some degree of complexity and variability that is not present in an autonomous plant. Being an obligate parasite, Cuscuta reflexa obtains its water, nutrients, and a significant part of its chemical constituents through its host plant, which forms a strong biochemical bond with the specific parasite, and has a significant impact on shaping the phytochemical profile of the latter. Such a relationship results in the host synthesizing secondary metabolites which can be translocated by the haustorial connections and accreted in the tissues of the parasite, and could become part of the phytochemical repertoire of the Cuscuta reflexa itself. It implies that the chemical composition of Cuscuta reflexa found on various host plants can differ drastically with research recording wide variations in phenolic content, flavonoid profiles and biological activities between the parasite growing on mango, tecoma, acacia or any of the many other plants it can be found on. This host-specific variation does not only involve quantitative differences in the concentration of the compounds but also in qualitative differences in the presence or absence of certain phytochemicals, and certain compounds even occur where Cuscuta reflexa feeds on certain host species. This variability is a daunting challenge to those researchers and developers who have to develop reproducible, standardized preparations that can be used in clinical applications because the biological activity of an extract cannot be assured between batches without host plant control and documentation. The seasonal change, geographical location and environment in which the growth occurs provides additional points of complication and as such there is a need to come up with a strong set of quality control parameters that can capture this natural variability and provide uniformity in therapeutic action.

The difficulties of phytochemical variability are also accompanied by the questions of extraction techniques and the standardization of Cuscuta reflexa preparations to conduct the research and even use in the therapy. The solvent used in extraction, water, ethanol, methanol, or any other organic solvent, has significant impacts on the compounds that are extracted out of the plant material and in what relative amounts, and each of the solvent systems yields an extract with a distinct phytochemical fingerprint and a biological activity profile. The solvents that are polar, like water or aqueous ethanol mixtures, extract glycosylated flavonoids, phenolic acids, and other polar ones, whereas less polar solvents, such as chloroform or hexane, extract aglycones, terpenoids, and sterols. The extracts obtained can have qualitatively dissimilar biological properties where there are fractions with strong antioxidant properties and those with good cytotoxic activity on cancer cells due to the different distribution of bioactive compounds with differences in polarities. This change which depends on the solvent makes it difficult to compare studies carried out by various research groups and results in the identification of the particular compounds that cause particular biological effects. Moreover, despite using the same solvent system, in some cases, the change in extraction parameters, such as temperature, time spent, particle size, and solvent-to-material ratio, can have a considerably strong impact on the extraction efficiency and the ultimate extract composition. Lack of universally agreed standards of Cuscuta reflexa extraction and characterization implies that every research group is effectively operating with a distinct preparation and restricts generalizability of results and hinders the development of clinical uses. To continue, standardized extraction procedures, approved reference standards, and approved methods of analysis to determine concentrations of marker compounds will be needed in the future to ensure that results can be replicated across studies and a solid basis of therapeutic development can be established.

FUTURE DIRECTIONS

In the future, the study of the anticancer potential of Cuscuta reflexa requires further development on numerous complementary axes in order to discover all of its potential as a therapeutic agent. Isolation and characterization of new bioactive compounds of this plant is a priority area of focus because the phytochemical studies carried out so far, though enlightening, must be considered only as tip of the iceberg of the chemical intricacy of the plant. The use of advanced chromatographic methods along with the complex spectroscopic methods such as high-performance liquid chromatography with diode array detection, liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy facilitate the separation and structural elucidation of even trace amounts of compounds, which may result in the identification of new chemical entities with novel mechanisms of action. The identification of two hitherto unreported 2H-pyran-2-one glucoside cuscutarosides A and B is an example of how natural product chemistry can still be useful in drug discovery. In flexible separation Bioassay-guided fractionation, where extracts are separated into fractions of increasing purity which are assayed to investigate biological activity at each stage of the process, offers a logical approach to purification of the isolated compounds mediating any given anticancer activity, whether by cytotoxicity assays, apoptosis induction measurements, or by a mechanism-based screen to detect a particular molecular pathway. These compounds can then be assessed on their respective activities, in comparison to the action of the parent extract to determine whether there might be synergies, and optimized using the tools of medicinal chemistry, i.e. structural modification to achieve increased potency, selectivity, or pharmacokinetic properties, should they have shown attractive therapeutic indices. The compounds can also be used as chemical probes in the study of biological pathways of interest in the study of cancer and offer a tool in the basic research even though they need not proceed to clinical development.

Lastly, the invention of new drug delivery methods using Cuscuta reflexa extracts will overcome a major food-to-drug barrier to use of plant-derived compounds namely poor bioavailability of most plant-derived polyphenolic flavonoids and other solubility-sensitive hydrophilic molecules. Oral administration of these compounds often results in excessive gut and hepatic metabolism to produce low and erratic concentrations to reach systemic circulation and target tissues . It is possible to circumvent these drawbacks using sophisticated drug delivery technologies, which have the potential to access the therapeutic power of Cuscuta reflexa bioactives. The compounds can also be encapsulated using nanoparticle-based formulations, such as polymeric nanoparticles, liposomes, solid lipid nanoparticles, and nanostructured lipid carriers, which protect the compounds against premature metabolism, promote absorption of the compounds across the biological barriers and provide sustained or targeted delivery of the compounds to tissue in tumors. The improved ability to target cells to tumor tissue through increased permeability and retention whereby leaky vasculature and deficient lymphatic drainage of tumor tissue favours the accumulation of nanoparticles in tumor tissue is an enhanced mechanism of targeting that may concentrate Cuscuta reflexa constituents at the site of action with minimal exposure to normal tissues. More can be done to increase tumor selectivity and cellular uptake with active targeting strategies, which entails the functionalization of nanoparticles with ligands that bind receptors overexpressed on cancer cells. Phytosomes, phospholipid complexes of plant components, are another strategy that is especially relevant to increase the bioavailability of flavonoid glycoside through improving the lipophilicity and membrane permeability of flavonoid glycoside. In topical uses, like skin cancer or tumors easily reached by needle, new methods of formulation like gels, creams and microneedle patches may allow local delivery with minimum systemic exposure. This type of formulation needs interdisciplinary cooperation of pharmacognosist, pharmaceutical scientists, and nanotechnologists, but the reward, which may be a way to turn poorly absorbed natural products into clinically useful medicines, justifies the investment. With all these different avenues of research coming together, the dream of Cuscuta reflexa as a safe, effective, and accessible source of anticancer therapy will be brought a bit closer to reality, and one may hope that this parasitic vine will someday start contributing to the treatment of one of the most difficult diseases facing humanity substantially.

CONCLUSION

The thorough overview of the phytochemical and anticancer features of the Cuscuta reflexa, which are discussed in this review, makes the given parasitic plant an extraordinarily promising source of lead molecules to be further used in the discovery of anticancer drugs, at the same time proving the critical role of further translation research to bridge the gap between the preclinical opportunities and the clinical usage. The travel via the botanical features, traditional applications, chemical intricacies, mechanistic understanding and therapeutic difficulties, the potential of the natural product that is still unutilized to the full extent, waiting the exact scientific research that could turn traditional information into some evidence-based treatment, is revealed. The phytochemical profile of Cuscuta reflexa is a catalog of bioactive compounds that have established relevance in the study of anticancer antioxidants quercetin and kaempferol flavonols that induce apoptosis through multiple pathways, anti-oxidants chlorogenic acid and dicaffeoylquinic acids with potent antioxidant and pro-oxidant activities depending on context, pro-oxidants and anti-inflammatory agents β-sitosterol and stigmasterol. This chemical diversity is not in vain redundant and it gives the plant the ability to interact with a range of molecular targets at the same time, attacking cancer by parallel perturbation of survival pathways, generation of oxidative stress, targeting of the apoptotic machinery, and regulation of the tumor-promoting inflammatory microenvironment. The network pharmacology data describing intricate relationships between Cuscuta reflexa compounds and major proteins involved in cancer-related processes are a contemporary scientific confirmation of the ancient knowledge on which the therapeutic uses of the plant have been based over the centuries proving that the multi-target nature of botanical medicines can be beneficial compared to the single-target paradigm of conventional pharmaceutical development. The evidence that cytotoxic effects occur in a wide variety of cancer cell lines, the explanation of apoptosis induction mechanisms by ROS-mediated mitochondrial depolarization and the apparent antioxidant-pro-oxidant duality of the paradoxical mechanism underlying selective cancer cell killing all point to a strong argument that Cuscuta reflexa contains clinically attractive anticancer activity and warrants further research.

REFERENCES

1. Gull N, Ahmad A, Rehman S. Ethanopharmacological relevance of Cuscuta reflexa Roxb. and its role as a hepato-protective agent: a comprehensive review. Phytochemistry Reviews. 2025 Oct 10:1-20.
2. Ahmed R, Ansary A, Bharadwaj A, Dutta KN, Sahariah BJ, Bora NS. A Comprehensive Review on The Phytochemical Profile, Ethnobotanical Uses and Pharmacological Activities of Cuscuta Reflexa Roxb.: An Asiatic Parasitic Vine. Fabad Eczac?l?k Bilimler Dergisi. 2025 Aug 8;50(2):447-80.
3. Adnan M, Chy MN, Kamal AM, Chowdhury MR, Islam MS, Hossain MA, Tareq AM, Bhuiyan MI, Uddin MN, Tahamina A, Azad MO. Unveiling pharmacological responses and potential targets insights of identified bioactive constituents of cuscuta reflexa roxb. Leaves through in vivo and in silico approaches. Pharmaceuticals. 2020 Mar 20;13(3):50.
4. Hayat S, Ashraf I. Phytochemical Profiling, Antimicrobial Potential, and Biological Activity of Cuscuta reflexa from Semi-Arid Regions of Pakistan. Sarhad Journal of Agriculture. 2025 Sep 1;41(330).
5. Gangarde P, Kuchekar B, Kuchekar A, Gawade A, Pujari R. Cuscuta reflexa roxb.: A special emphasis on its anticancer, antimicrobial, anti-inflammatory, immunomodulatory potential. Research Journal of Pharmacy and Technology. 2024;17(10):5055-61.
6. Khan MS, Rahmatullah M. Advances in Efficacy of Cuscuta Reflexa Leaf in Diabetes Treatment. Australian Herbal Insight. 2024 Jan 24;7(1):1-8.
7. Elasbali AM, Al-Soud WA, Mousa Elayyan AE, Alhassan HH, Danciu C, Elfaki EM, Alharethi SH, Alharbi B, Alanazi HH, Mohtadi ME, Patel M. Antioxidative and ROS-dependent apoptotic effects of Cuscuta reflexa Roxb. stem against human lung cancer: network pharmacology and in vitro experimental validation. Journal of Biomolecular Structure and Dynamics. 2024 Dec 9;42(21):11651-76.
8. Biswas PC, Nair SS, Chauhan N, Dhuriya A, Kothari LP, Singh VH, Srivastav Y, Sharma P. PHYTOCHEMICAL INVESTIGATION AND ANTIOXIDANT POTENTIAL OF CUSCUTA REFLEXA METHANOL LEAF EXTRACT: QUANTIFICATION OF FLAVONOID FRACTION, TOTAL GLYCOSIDE CONTENT AND FREE RADICAL SCAVENGING ACTIVITIES. Biochemical & Cellular Archives. 2025 Apr 1;25(1).
9. Ahmed R, Bhattacharya K, Nandan Dutta K, Das D, Sahariah BJ, Deka S, Bora NS. Harnessing the anti-inflammatory potential of Cuscuta reflexa Roxb.: a comprehensive study on a leafless parasitic weed using chromatographic, in silico, and in vitro methods. Natural Product Research. 2025 Mar 7:1-7.
10. Nadeem M, Mumtaz MW, Danish M, Rashid U, Mukhtar H, Irfan A, Anwar F, Saari N. UHPLC-QTOF-MS/MS metabolites profiling and antioxidant/antidiabetic attributes of Cuscuta reflexa grown on Casearia tomentosa: exploring phytochemicals role via molecular docking. International Journal of Food Properties. 2020 Jan 1;23(1):918-40.
11. Khan S, Alam S, Rehman S, Siddiqui N, Azhar M. Physicochemical and phytochemical characterization of Cuscuta reflexa Roxb. along with its HPLC profiling. INTERNATIONAL JOURNAL OF PHARMACOGNOSY. 2025;6(1):19-26.
12. Khan M, Mishra A. Unraveling the Therapeutic Potential of Miracle Plant ‘Aftimoon’in Disease Prevention and Treatment: A Comprehensive Review. Journal of Drug Delivery & Therapeutics. 2024 May 1;14(5).
13. Akhtar U, Khurshid Y, El-Aarag B, Syed B, Khan IA, Parang K, Ahmed A. Proteomic characterization and cytotoxic potential of proteins from Cuscuta (Cuscuta epithymum (L.) crude herbal product against MCF-7 human breast cancer cell line. BMC Complementary Medicine and Therapies. 2024 May 20;24(1):195.
14. Begum NF, Ramadoss R, Yadalam PK, Ramani P, Ramalingam K, Begum III NF, kumar Yadalam P. Phytochemical targeting of nerve growth factor by thymoquinone and cuscutin: a molecular dynamics simulation study. Cureus. 2024 Jul 3;16(7).
15. Kaushik ML, Goutam N, Ashawat MS. Protective effects of ethanolic extract of Cuscuta reflexa Roxb. against ethylene glycol-induced hyperoxaluria and urolithiasis in rats. Journal of Herbmed Pharmacology. 2025 Oct 1;14(4):482-95.
16. Aljorani RH, Al-Zubaidy AA, Abdali NT. Effect of Cuscuta reflexa Extract in Mitigating Testosterone-Induced Benign Prostatic Hyperplasia in Rats: Targeting Inflammation and Oxidative Stress. Al-Rafidain Journal of Medical Sciences (ISSN 2789-3219). 2025 Apr 6;8(2):35-41.
17. Ramezan D, Farrokhzad Y, Zargar M, Stybayev G, Kipshakbayeva G, Baitelenova A. An insight into Cuscuta campestris as a medicinal plant: phytochemical variation of Cuscuta campestris with various host plants. Agriculture. 2023 Mar 27;13(4):770.
18. Ara I, Kalam MA, Maqbool M, Zehravi M. Phytochemical standardization and anti-anxiety (Izterab-e-Nafsani) study of Aftimoon Hindi (Cuscuta reflexa Roxb.) on an animal model. CellMed. 2021;11(3).
19. Shewale H, Nagare N, Salunke B, Raut H, Shaikh MR. Development and Characterization of Herbal Shampoo from Cuscuta Reflexa. International Journal of Scientific Research and Technology. 2025 Apr 22.
20. Singh Y, Paswan SK, Kumar R, Otia MK, Acharya S, Kumar D, Keshamma E. Plant & Its Derivative Shows Therapeutic Activity on Neuroprotective Effect. Journal for Research in Applied Sciences and Biotechnology. 2022 Jun 30;1(2):10-24.
21. Muhammad N, Ullah S, Abu-Izneid T, Rauf A, Shehzad O, Atif M, Khan H, Naz H, Herrera-Calderon O, Khalil AA, Uddin MS. The pharmacological basis of Cuscuta reflexa whole plant as an antiemetic agent in pigeons. Toxicology Reports. 2020 Jan 1;7:1305-10.
22. Sharma N, Kumar V, Gupta N. Phytochemical analysis, antimicrobial and antioxidant activity of methanolic extract of Cuscuta reflexa stem and its fractions. Vegetos. 2021 Dec;34(4):876-81.
23. Chishti MA, Akram M, Ahmet F. Cuscuta reflexa traditional miracle plant: A review on ethnomedicinal and therapeutic potential. Int Arch Integr Med. 2024 Jan 1;11(1):1-8.
24. Mishra S, Alhodieb FS, Barkat MA, Hassan MZ, Barkat HA, Ali R, Alam P, Alam O. Antitumor and hepatoprotective effect of Cuscuta reflexa Roxb. in a murine model of colon cancer. Journal of ethnopharmacology. 2022 Jan 10;282:114597.
25. Sidhu AR, Basit A, Hayat A, Mangrio S, Arain S, Khalid T, Mohamed HI, Elhakem A. Quality characteristics, phytochemical analysis, and antioxidant of extract Cuscuta reflexa (Roxb.). Notulae Botanicae Horti Agrobotanici Cluj-Napoca. 2022 Sep 6;50(3):12691-.
26. Hayat S, Ashraf I. Phytochemical Profiling, Antimicrobial Potential, and Biological Activity of Cuscuta reflexa from Semi-Arid Regions of Pakistan. Sarhad Journal of Agriculture. 2025 Sep 1;41(330).
27. Sarwade PP, SR SK, Kumar R, Pant NC, Gaisamudre KN. Therapeutic potential of Curcuma longa and its constituents role in the treatment of multiple sclerosis. Asian Journal of Pharmaceutical Research and Development. 2024 Dec 15;12(6):63-70.
28. Sarwade PP, Srinandhinidevi KM, Dangwal K, Maurya C, Otia M, KUMAR S, PRAKASH J, GAISAMUDRE SK. Role of pyrimidine derivatives in the treatment of cancer. J Res Appl Sci Biotechnol. 2024;3:181-93.
29. Sarwade PP, Bongale MM, Mittal N, Chand S, Vijayalakshmi K, Khongshei R, Gaisamudre KN. A detailed study of Hibiscus rosa sinesis L: Phytochemistry, pharmacological activities therapeutic uses and its antimicrobial, antioxidant activities. Asian Journal of Pharmaceutical Research and Development. 2025 Feb 15;13(1):138-46.
30. Mishra MK, Rajput A, Yadav MK, Sinha S, Bhaskar R, Sarwade PP. Allium sativum L. It's Therapeutic uses and potential use as an anticancer agent: A Review. Journal of Pharmacy and Pharmaceutical Science. 2024 Jul 4;13(9):310-20.
31. Sarwade PP, Nisha KB, Hari I, Tawale H, Ambika J, Thaiyalnayagi S, Yadav MK, Gaisamudre KN, Geetha M. Phytochemical analysis, antioxidant activity of wild medicinal plants of Himalayan range. J. Res. Appl. Sci. Biotechnol. 2024;3(5):131-46.
32. SR SK, Bongale MM, Sarwade PP, Vijayalakshmi K, Goswami M, Khongshei R, Gaisamudre KN. Ocimum Sanctum: Phytochemistry, Therapeutic Uses Pharmacological Activities and Its Anticancer Activities. Asian Journal of Pharmaceutical Research and Development. 2025 Apr 15;13(2):119-25.
33. Gaisamudre KN, Sarwade PP, Sonwani K, Chand S, Goswami M, Kaur H, Pant NC. Musa Paradisiaca It's Phytochemistry, Traditional Uses And Pharmacological Activities. Asian Journal of Pharmaceutical Research and Development. 2025 Dec 15;13(6):273-85.
34. Sarwade PP, Maurya C, Pant NC, Rai M, Bhakuni N, Gupta VL, Prakash J, Gaisamudre KN. Cascabela thevetia ethnobotanical, phytochemistry, pharmacological activities and medicinal uses: A detailed study. JOURNAL FOR RESEARCH IN APPLIED SCIENCES AND BIOTECHNOLOGY ??????????: Stallion Publication. 2024;3(5):211-21.
35. Sarwade P, Gaisamudre K, Swami O, Prabhu S, Sivasamy KJ, Sati R, Kumar R. Aldehyde-Mediated Neurotoxicity and Lutein Intervention: A Novel Therapeutic Strategy for Alzheimer’s Disease.
36. Sarwade JM, Gujar M, Shinde J, Thombare P, Rupnur P, Arbad G. Artificial intelligence-machine learning strategies for crop leaf disease detection. In2024 4th International Conference on Ubiquitous Computing and Intelligent Information Systems (ICUIS) 2024 Dec 12 (pp. 57-61). IEEE.
37. Gaisamudre KN, Sarwade PP, Sonwani K, Chand S, Mehta R, Pant NC. Exploring Lantana camara: A comprehensive insight into its bioactive constituents and therapeutic potential. Asian Journal of Pharmaceutical Research and Development. 2025 Dec 15;13(6):286-96.
38. Santosh Kumar SR, Bongale MM, Maurya C, Yuvraj VL, Dubey SA, Sarwade PP. Investigation of Phytochemical and Antidepressants Activity of Cinnamon Powder Extract. Life.;20:21.
39. Sarwade P, Gaisamudre K, Sonwani K, Jasra K, Rawat K, Saha P, Kumar R. Integrative Review on Nyctanthes arbor-tristis: Exploring its Botanical Identity, Bioactive Compounds, and Biomedical Applications.
40. Sarwade P, Gaisamudre K, Gupta L, Arshad MZ, Gupta J, Kumar R, Sivasamy SP. Unlocking the Benefits of Antioxidants Beta Carotene and Quercetin Potential for Female Health.
41. Sarwade PP, Gaisamudre KN, Kumar R, Gajendhini S. A Detailed Study of Aloe Barbadensis Phytochemistry, Taxonomy and Its Anticancer Activity.
42. Suresh V, Sruthi V, Padmaja B, Asha VV. In vitro anti-inflammatory and anti-cancer activities of Cuscuta reflexa Roxb. Journal of ethnopharmacology. 2011 Apr 12;134(3):872-7.
43. Chatterjee D, Sahu RK, Jha AK, Dwivedi J. Evaluation of antitumor activity of Cuscuta reflexa Roxb (Cuscutaceae) against Ehrlich ascites carcinoma in Swiss albino mice. Tropical Journal of Pharmaceutical Research. 2011;10(4):447-54.
44. Ali I, Suhail M, Fazil M, Ahmad B, Sayeed A, Naqshbandi MF, Azam A. Anti-cancer and anti-oxidant potencies of Cuscuta reflexa Roxb. plant extracts. Am. J. Adv. Drug Deliv. 2019;14(92):e113.
45. Mishra S, Alhodieb FS, Barkat MA, Hassan MZ, Barkat HA, Ali R, Alam P, Alam O. Antitumor and hepatoprotective effect of Cuscuta reflexa Roxb. in a murine model of colon cancer. Journal of ethnopharmacology. 2022 Jan 10;282:114597.
46. Gangarde P, Kuchekar B, Kuchekar A, Gawade A, Pujari R. Cuscuta reflexa roxb.: A special emphasis on its anticancer, antimicrobial, anti-inflammatory, immunomodulatory potential. Research Journal of Pharmacy and Technology. 2024;17(10):5055-61.
47. Bhagat M, Arora JS, Saxena AK. In vitro and in vivo antiproliferative potential of Cuscuta reflexa Roxb. Journal of Pharmacy Research. 2013 Jul 1;6(7):690-5.
48. Gull N, Ahmad A, Rehman S. Ethanopharmacological relevance of Cuscuta reflexa Roxb. and its role as a hepato-protective agent: a comprehensive review. Phytochemistry Reviews. 2025 Oct 10:1-20.
49. Udavant PB, Satyanarayana SV, Upasani CD. Preliminary screening of Cuscuta reflexa stems for anti inflammatory and cytotoxic activity. Asian Pacific Journal of Tropical Biomedicine. 2012 Jan 1;2(3):S1303-7.
50. Elasbali AM, Al-Soud WA, Mousa Elayyan AE, Alhassan HH, Danciu C, Elfaki EM, Alharethi SH, Alharbi B, Alanazi HH, Mohtadi ME, Patel M. Antioxidative and ROS-dependent apoptotic effects of Cuscuta reflexa Roxb. stem against human lung cancer: network pharmacology and in vitro experimental validation. Journal of Biomolecular Structure and Dynamics. 2024 Dec 9;42(21):11651-76.
51. Bhagat M, Saxena A, Bushan S, Arora JS, Saxena AK. Cytotoxic effect of Cuscuta reflexa Roxb. and induction of apoptosis in human promyelocytic leukemia HL-60 cells. Indian J Biochem Biophys. 2015 Jun 1;52:232-8.
52. Riaz M, Bilal A, Ali MS, Fatima I, Faisal A, Sherkheli MA, Asghar A. Natural products from Cuscuta reflexa Roxb. with antiproliferation activities in HCT116 colorectal cell lines. Natural product research. 2017 Mar 4;31(5):583-7.
53. Bhagat M, Saxena AK. In vitro anti-proliferative, anti-bacterial potential and induction of DNA strand break of partially purified Cuscuta reflexa Roxb. International Journal. 2011 Oct 1;307.
54. Rai DK, Sharma V, Pal K, Gupta RK. Comparative phytochemical analysis of Cuscuta reflexa Roxb. Parasite grown on north India by GC-MS. Trop Plant Res. 2016;3(2):428-43.
55. Ali SR, Farooq AD, Haque S, Mudassar MA, Faizi S. Cuscuta reflexa Roxb. and Its Pure Compounds-induced Micronuclei in Plant Cells and Downregulation of EGFR Expression in NCI-H460 Cell Line. MADINAT AL-HIKMAH. 2017;60(1):13.
56. Vijikumar S, Ramanathan K, Devi BP. Cuscuta reflexa Roxb—A wonderful miracle plant in ethnomedicine. Indian J Nat Sci. 2011;976:997.
57. Sidhu AR, Basit A, Hayat A, Mangrio S, Arain S, Khalid T, Mohamed HI, Elhakem A. Quality characteristics, phytochemical analysis, and antioxidant of extract Cuscuta reflexa (Roxb.). Notulae Botanicae Horti Agrobotanici Cluj-Napoca. 2022 Sep 6;50(3):12691-.
58. Saini P, Mithal R, Menghani E. A parasitic medicinal plant Cuscuta reflexa: an overview. Int. J. Sci. Eng. Res. 2015 Dec;6:951-9.
59. Ahmed R, Ansary A, Bharadwaj A, Dutta KN, Sahariah BJ, Bora NS. A Comprehensive Review on The Phytochemical Profile, Ethnobotanical Uses and Pharmacological Activities of Cuscuta Reflexa Roxb.: An Asiatic Parasitic Vine. Fabad Eczac?l?k Bilimler Dergisi. 2025 Aug 8;50(2):447-80.
60. Ansari A, Viquar U, Kazmi MH. Aftimoon (Cuscuta reflexa Roxb.): a parasitic plant with therapeutic potentials. Acta Scientific Pharmaceutical Sciences. 2020;4(11):90-7.
61. Hayat S, Ashraf I. Phytochemical Profiling, Antimicrobial Potential, and Biological Activity of Cuscuta reflexa from Semi-Arid Regions of Pakistan. Sarhad Journal of Agriculture. 2025 Sep 1;41(330).
62. Sharma N, Kumar V, Gupta N. Phytochemical analysis, antimicrobial and antioxidant activity of methanolic extract of Cuscuta reflexa stem and its fractions. Vegetos. 2021 Dec;34(4):876-81.